The main finding of this study is that the expression level of SCGN alters with the progression of ccRCC, with the highest expression at the beginning of tumor formation and decreases with increasing malignancy and metastasis, and it is also heterogeneously expressed in different malignant regions within the same tumor. Here, SCGN is linked to nonpapillary renal cell carcinoma.